Derazantinib hydrochloride is under clinical development by Merck & Co and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Derazantinib hydrochloride’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 25 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 25 Nov 2022 increased Derazantinib hydrochloride’s LoA and PTSR for Hepatocellular Carcinoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Derazantinib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Derazantinib hydrochloride overview
Deranzantinib hydrchloride (ARQ-087) is under development for the treatment of intrahepatic cholangiocarcinoma (iCCA), adenocarcinoma of the gastroesophageal junction, adrenocortical tumors, advanced solid tumors and urothelial cell carcinoma. The drug candidate is administered orally. ARQ-087 is an inhibitor of pan-fibroblast growth factor receptor (FGFR) and CSF1R. The drug candidate is based on proprietary structure-based drug design technology known as the ArQule Kinase Inhibitor Platform (AKIP).
Merck & Co overview
Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Quick View Derazantinib hydrochloride LOA Data
|Highest Development Stage|